Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 12/20 | 0.42 |
| ▸ | RAF1 | P04049 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TNF | P01375 | 1/20 | 0.31 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.31 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9930497 | 0.90 | BRAF (0.35) | BRAFKMT2ATP53LMNAMAPT | |
| SCHEMBL9930389 | 0.83 | BRAF (0.60) | BRAFRAF1CSF1R | |
| SCHEMBL14574660 | 0.81 | BRAF (0.48) | BRAFRAF1TP53LMNAMAPT | |
| SCHEMBL9930333 | 0.80 | BRAF (0.49) | BRAFRAF1TP53CSF1R | |
| SCHEMBL9930834 | 0.80 | BRAF (0.49) | BRAFRAF1TP53CSF1R | |
| SCHEMBL9930556 | 0.79 | BRAF (0.48) | BRAFRAF1TP53CSF1R | |
| SCHEMBL9930341 | 0.79 | BRAF (0.48) | BRAFRAF1TP53CSF1R | |
| SCHEMBL14574885 | 0.79 | BRAF (0.38) | BRAFRAF1CSF1R | |
| SCHEMBL14574813 | 0.79 | BRAF (0.56) | BRAF | |
| SCHEMBL9930345 | 0.79 | BRAF (0.37) | BRAFTP53LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | BRAF 1/4885RAF1 2/4885TDP1 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.